• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.强迫症患者对5-羟色胺再摄取抑制剂的反应不受常见的细胞色素P450 2D6基因多态性影响。
Int J Psychiatry Clin Pract. 2009 Nov;13(1):345-348. doi: 10.3109/13651500902903016. Epub 2009 Jun 1.
2
Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.帕罗西汀：在治疗惊恐障碍中的药理学和治疗潜力的综述。
CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.
3
Serotonin and Norepinephrine Reuptake Inhibitors.5-羟色胺及去甲肾上腺素再摄取抑制剂
Handb Exp Pharmacol. 2019;250:145-180. doi: 10.1007/164_2018_164.
4
A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.帕罗西汀与文拉法辛治疗强迫症的双盲转换研究。
J Clin Psychiatry. 2004 Jan;65(1):37-43. doi: 10.4088/jcp.v65n0106.
5
Biological therapies for obsessive-compulsive disorder.
J Psychiatr Pract. 2000 May;6(3):113-28. doi: 10.1097/00131746-200005000-00002.
6
New treatment options for OCD.强迫症的新治疗选择。
Int J Psychiatry Clin Pract. 2007;11 Suppl 2:24-30. doi: 10.1080/13651500701388534.
7
Refining treatment approaches in obsessive-compulsive disorder.强迫症治疗方法的优化
Int Clin Psychopharmacol. 1996 Dec;11 Suppl 5:13-22. doi: 10.1097/00004850-199612005-00003.
8
SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder?5-羟色胺再摄取抑制剂是治疗强迫症的药理学替代药物？
Innov Clin Neurosci. 2011 Jun;8(6):10-4.
9
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.人细胞色素 P450 2D6 的多态性及其临床意义：第二部分。
Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.
10
Orgasm, Serotonin Reuptake Inhibition, and Plasma Oxytocin in Obsessive-Compulsive Disorder. Gleaning From a Distant Randomized Clinical Trial.强迫症中的性高潮、5-羟色胺再摄取抑制与血浆催产素。从一项远距离随机临床试验中收集信息
Sex Med. 2016 Sep;4(3):e145-55. doi: 10.1016/j.esxm.2016.04.002. Epub 2016 Jun 17.

引用本文的文献

1
Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders.强迫症临床进展：国际强迫症谱系及相关障碍学院立场声明。
Int Clin Psychopharmacol. 2020 Jul;35(4):173-193. doi: 10.1097/YIC.0000000000000314.
2
Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?MDR1 基因 G2677T 多态性是否会影响斯洛伐克抑郁症患者对帕罗西汀的治疗反应？
Med Sci Monit. 2018 May 13;24:3136-3145. doi: 10.12659/MSM.907434.
3
Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.儿童中细胞色素P450相关药物的临床药物遗传学
J Pers Med. 2017 Nov 2;7(4):14. doi: 10.3390/jpm7040014.
4
PharmGKB summary: venlafaxine pathway.药物基因组学知识库总结：文拉法辛途径。
Pharmacogenet Genomics. 2014 Jan;24(1):62-72. doi: 10.1097/FPC.0000000000000003.

本文引用的文献

1
Practice guideline for the treatment of patients with obsessive-compulsive disorder.强迫症患者治疗实践指南。
Am J Psychiatry. 2007 Jul;164(7 Suppl):5-53.
2
Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.在一项随机双盲试验中，血清素相关基因对强迫症患者帕罗西汀和文拉法辛反应的预测
J Clin Psychiatry. 2007 May;68(5):747-53. doi: 10.4088/jcp.v68n0512.
3
Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.一个种族多样化人群中11个I期药物代谢基因的遗传变异。
Pharmacogenomics. 2004 Oct;5(7):895-931. doi: 10.1517/14622416.5.7.895.
4
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.一种新的内含子突变，2988G>A，对白种人细胞色素P450 2D6功能受损具有高度预测性。
Clin Pharmacol Ther. 2004 Aug;76(2):128-38. doi: 10.1016/j.clpt.2004.04.009.
5
A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.帕罗西汀与文拉法辛治疗强迫症的双盲转换研究。
J Clin Psychiatry. 2004 Jan;65(1):37-43. doi: 10.4088/jcp.v65n0106.
6
Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.帕罗西汀用于强迫症的急性及长期治疗与复发预防。
J Clin Psychiatry. 2003 Sep;64(9):1113-21. doi: 10.4088/jcp.v64n0919.
7
A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.文拉法辛与帕罗西汀治疗强迫症的双盲对照研究
J Clin Psychopharmacol. 2003 Dec;23(6):568-75. doi: 10.1097/01.jcp.0000095342.32154.54.
8
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.欧洲白种人、亚洲人、非洲人及其后裔中CYP2D6等位基因频率。
Pharmacogenomics. 2002 Mar;3(2):229-43. doi: 10.1517/14622416.3.2.229.
9
High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum.高效液相色谱法用于筛查和定量人血清中的七种选择性5-羟色胺再摄取抑制剂。
J Chromatogr B Biomed Sci Appl. 2001 Sep 25;761(2):147-58. doi: 10.1016/s0378-4347(01)00305-x.
10
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.基于CYP2D6和CYP2C19基因型的抗抑郁药剂量推荐：迈向亚群特异性剂量的第一步。
Acta Psychiatr Scand. 2001 Sep;104(3):173-92. doi: 10.1034/j.1600-0447.2001.00299.x.

强迫症患者对5-羟色胺再摄取抑制剂的反应不受常见的细胞色素P450 2D6基因多态性影响。

Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.

作者信息

Van Nieuwerburgh Filip C W, Denys Damiaan A J P, Westenberg Herman G M, Deforce Dieter L D

出版信息

Int J Psychiatry Clin Pract. 2009 Nov;13(1):345-348. doi: 10.3109/13651500902903016. Epub 2009 Jun 1.

DOI:10.3109/13651500902903016
PMID:20174590
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2824234/
Abstract

The cornerstone of pharmacotherapy for OCD is serotonin reuptake inhibition, either with clomipramine or with selective serotonin reuptake inhibitors (SSRIs). In spite of the success of serotonin reuptake inhibiting drugs, nearly half of OCD patients do not respond to treatment. Treatment response may be affected by genetic polymorphisms of the P450 metabolic system. The four most common enzyme-activity reducing polymorphisms of the P450 CYP2D6 enzyme were determined in 91 outpatients with primary OCD according to DSM-IV criteria, receiving dosages titrated upward to 300 mg/day of venlafaxine or 60 mg/day of paroxetine, using a fixed dosing schedule. Our results show that the investigated CYP2D6 polymorphisms are not a decisive factor in the response to paroxetine and venlafaxine treatment in OCD in spite of their highly significant effect on the blood levels of these medicines.

摘要

强迫症药物治疗的基石是5-羟色胺再摄取抑制，可使用氯米帕明或选择性5-羟色胺再摄取抑制剂（SSRI）。尽管5-羟色胺再摄取抑制药物取得了成功，但近一半的强迫症患者对治疗无反应。治疗反应可能受P450代谢系统基因多态性的影响。根据《精神疾病诊断与统计手册》第四版标准，对91例原发性强迫症门诊患者进行了研究，这些患者使用固定给药方案，接受剂量逐渐增加至文拉法辛300mg/天或帕罗西汀60mg/天的治疗，测定了P450 CYP2D6酶最常见的四种降低酶活性的基因多态性。我们的结果表明，尽管所研究的CYP2D6基因多态性对这些药物的血药浓度有高度显著影响，但它们并非强迫症患者对帕罗西汀和文拉法辛治疗反应的决定性因素。